Latest Amgen Stories
THOUSAND OAKS, Calif., Nov.
Thirteen Presentations Include New Analyses of PCSK9 Inhibitor at Upcoming American Heart Association Scientific Sessions THOUSAND OAKS, Calif., Nov.
Foundation's Commitment to Science, Technology, Engineering and Math (STEM) Education Surpasses $100 Million Milestone THOUSAND OAKS, Calif., Nov.
Brodalumab Meets All Primary and All Key Secondary Endpoints THOUSAND OAKS, Calif. and LONDON, Nov.
Mnemosyne appoints Vanessa King, Ph.D. Chief Executive Officer. Dr.
THOUSAND OAKS, Calif., Nov. 10, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the U.S.
THOUSAND OAKS, Calif., Nov. 6, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will participate at the Credit Suisse Annual Healthcare Conference on Tuesday, Nov.
Presentations Including Pivotal Data on Kyprolis® and Blinatumomab, a BiTE® Immunotherapy, Demonstrate Company's Continued Commitment to Developing Treatments for Difficult-to-Treat Blood Cancers THOUSAND
Board members to help Cloud Pharmaceuticals further penetrate the cloud-based drug design and development market RESEARCH TRIANGLE PARK, N.C., Nov.
RnRMarketResearch.com adds “Colon Cancer and Ovarian Cancer – Pipeline Review, H2 2014” to its store.
- A morbid dread of being buried alive. Also spelled 'taphiphobia'.